Revised SPC: Madopar (levodopa and benserazide)

Revised SPC: Madopar (levodopa and benserazide) – all formulations
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Gastrointestinal disorders | Mental health and illness | Nutritional and metabolic disorders
Summary
Section 4.5 now states that the concomitant administration of antipsychotics with dopamine-receptor blocking properties might antagonise the antiparkinsonian effects of levodopa-benserazide. In addition levodopa may reduce antipsychotic effects of these drugs.
UKMi comment
A statement that domperidone may increase the bioavailability of levodopa by stimulation of gastric emptying has also been added to section 4.5.
Related links:

Revised SPC: Madopar (levodopa and benserazide) – all formulations